Compared to other MDM2 inhibitors, its pharmacokinetic properties allow for dose optimization, potentially reducing myelosuppressive side effects.407,408 A phase I clinical trial (NCT03449381) has been conducted since February 2018 to assess the optimal dose of BI-907828 for patients with different types of advanced cancer (solid tumors). The gene discussed is MDM2; the disease is cancer.